Ophthalmology News and Research

RSS

Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.

Brief empathy training program improves resident physicians interactions with patients

Resident physicians' participation in a brief training program designed to increase empathy with their patients produced significant improvement in how patients perceived their interactions with the residents.

8 May 2012

Amakem presents key preclinical data on AMA0076 at ARVO meeting

Amakem NV, a kinase platform company focusing on ophthalmology, presented key preclinical data on its potent, locally active Rho Kinase (ROCK) inhibitor AMA0076 at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held at Fort Lauderdale, US from 6 - 10 May. The ARVO meeting is the world's largest gathering of international eye and vision researchers.

8 May 2012

Metformin blocks uveitis in laboratory rats

University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.

8 May 2012

Repeating trinucleotide a strong predictor of Fuchs' dystrophy

Mayo Clinic and University of Oregon researchers have confirmed that a genetic factor called a repeating trinucleotide is a strong predictor of an individual's risk of developing the eye condition Fuchs' dystrophy. The findings were being presented today at the annual conference of the Association for Research in Vision and Ophthalmology in Orlando, Fla.

8 May 2012

Cheaper anti-blindness drug could save NHS £85 million annually

Avastin (bevacizumab), which is used to treat wet age-related macular degeneration – the most common cause of blindness among the elderly costs only £60 per injection. But despite trials showing it is no less effective, another drug, Lucentis, is the current official choice, even though it costs £700 per shot. Avastin is intended to treat bowel cancer, but research by the National Institute for Health Research has shown that it also works just as effectively and safely as Lucentis in treating Wet AMD.

8 May 2012

New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.

8 May 2012

No functional difference in effects of Lucentis and Avastin on preventing vision loss

The one year results from a study into whether two drug treatments (Lucentis and Avastin), are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD), have been reported today at an international research meeting in Fort Lauderdale, Florida. The findings will also appear online shortly in the leading journal Ophthalmology.

7 May 2012

Oral nutriceutical restores vision to otherwise hopeless patients facing permanent loss

There may be new found hope for patients whose vision is threatened when medicine injected directly into the eyes fails to cause abnormal blood vessels to recede. While injectable drugs called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle and have become the standard of care for patients with the fast-progressive form of macular degeneration, they are not foolproof.

7 May 2012

Bionic eye helps two blind men see for the first time in 20 years

In a medical breakthrough two blind men have regained partial sight for the first time in more than 20 years after receiving a “bionic eye”. Scientists said the first clinical trials of the microchip eye implant, which measures just 3mm across and is fitted behind the eyeball, have proved successful and “exceeded expectations”.

4 May 2012

STAAR Surgical first quarter total revenue increases 4% to $15.5M

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that sales of its Visian ICL product in the first quarter ended March 30, 2012 increased 25% to $8.6 million.

3 May 2012

Levetiracetam to be tested for seizure management in malaria endemic regions

Michigan State University researchers, with the help of a groundbreaking medical device, are starting a clinical trial in Africa they hope will provide relief for the hundreds of thousands of children who survive cerebral malaria but are left stricken with epilepsy or other neurologic disorders.

2 May 2012

MCW professor receives 2012 Founders Award at AMSSM meeting

Craig Young, MD, was awarded the 2012 Founders Award at the 21th Annual Meeting of the American Medical Society for Sports Medicine, in Atlanta on April 24, 2012. The award is not given annually, but is bestowed when AMSSM leadership determines that someone exemplifies the best that a sports medicine physician can be and do.

27 Apr 2012

University of Kentucky researchers make major breakthrough in GA

University of Kentucky researchers, led by Dr. Jayakrishna Ambati, have made a major breakthrough in the "dry" form of age-related macular degeneration known as geographic atrophy.

27 Apr 2012

Case study in the Journal of AAPOS highlights need for vigilance

It has been estimated that roughly 4% to 6% of child abuse victims present first to an ophthalmologist. In a case study in the April issue of the Journal of American Association of Pediatric Ophthalmology and Strabismus, doctors at the University of Washington and the Seattle Children's Hospital describe a case of a 13-month-old girl who was initially diagnosed with corneal abrasion and a mild infection. She was eventually identified as a victim of child abuse.

26 Apr 2012

Computational adaptive optics for real-time in-vivo applications

Real-time, 3-D microscopic tissue imaging could be a revolution for medical fields such as cancer diagnosis, minimally invasive surgery and ophthalmology. University of Illinois researchers have developed a technique to computationally correct for aberrations in optical tomography, bringing the future of medical imaging into focus.

24 Apr 2012

Novel technological treatment for Leber Hereditary Optic Neuropathy

A research team, led by John Guy, M.D., professor of ophthalmology at Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, has pioneered a novel technological treatment for Leber Hereditary Optic Neuropathy (LHON), an inherited genetic defect that causes rapid, permanent, and bilateral loss of vision in people of all ages, but primarily males ages 20-40.

24 Apr 2012

ACT announces dosing of third patient in dry AMD Phase I/II trial

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the dosing of the third patient in its Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells.

21 Apr 2012

Regenerative medicine research offers hope for the blind

The University College London researchers transplanted immature vision cells directly into the mouse retina. They noted that within weeks the cells began to integrate into the retina and the researchers, led by Prof Robin Ali in the university’s Institute of Ophthalmology, were able to show that vision began to return to the mice.

19 Apr 2012

ARVO to host presentation of results from two clinical trials on neovascular AMD

ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

19 Apr 2012

Caffeine increases eye's ability to produce tears

Researchers at the University of Tokyo's School of Medicine have shown for the first time that caffeine intake can significantly increase the eye's ability to produce tears, a finding that could improve treatment of dry eye syndrome. This common eye condition affects about four million people age 50 and older in the United States.

18 Apr 2012